Pyrethroid-resistant malaria vector Anopheles gambiae restored susceptibility after pre-exposure to piperonyl-butoxide: results from country-wide insecticide resistance monitoring in Tanzania, 2023
The evidence of widespread pyrethroid resistance of the major malaria vector justifies the decision made by the Tanzania National Malaria Control Programme to transition to PBO-based ITNs. Without this switch, the gains achieved in malaria control could be compromised. Equally important, the lack of full restoration to susceptibility observed in three sentinel districts upon pre-exposure to PBO merits close monitoring, as there could be other underlying resistance mechanisms besides oxidase metabolic resistance.
Authors
- Sigsbert Mkude
- Nicodem James Govella (ORCID: https://orcid.org/0000-0001-5460-9629)
- Charles Dismas Mwalimu (ORCID: https://orcid.org/0000-0002-2143-222X)
- Samson Kiware (ORCID: https://orcid.org/0000-0001-7252-520X)
- Adeline Chan
- Bilali Kabula (ORCID: https://orcid.org/0000-0002-7374-169X)
- Naomi Serbantez (ORCID: https://orcid.org/0000-0003-0204-7796)
- Sarah-Blythe Ballard (ORCID: https://orcid.org/0000-0003-3581-5771)
- J. Lavelle Michael
- Yeromin P. Mlacha (ORCID: https://orcid.org/0000-0001-8879-7066)
- Victor Mero
- Samwel L. Nhiga
- Said Abbasi
Institutions
- Ifakara Health Institute (TZ)
- Centers for Disease Control and Prevention (US)
- University of Dar es Salaam (TZ)
- U.S. President's Malaria Initiative (US)
- Ministry of Health, Community Development, Gender, Elderly and Children (TZ)
- National Institute for Medical Research (TZ)
- Population Services International (ZM)
Publication Details
- Journal
- Malaria Journal
- Published
- 2024-12-21
- DOI
- https://doi.org/10.1186/s12936-024-05211-7
- Citations
- 14
- Primary Topic
- Malaria Research and Control
- Type
- article
- Field-Weighted Citation Impact
- 7.60
Funders
- United States Agency for International Development
- UK Research and Innovation
- European Commission
- Foreign, Commonwealth and Development Office
- President's Malaria Initiative
- Medical Research Council
- European and Developing Countries Clinical Trials Partnership